Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Probiotics in neurodegenerative disorders
  • Home
  • /
  • Probiotics in neurodegenerative disorders
  1. Home /
  2. Archives /
  3. Vol. 95 (2026) /
  4. Health Sciences

Probiotics in neurodegenerative disorders

Authors

  • Mikołaj Szczęsny https://orcid.org/0009-0003-1010-9712
  • Rafał Szarek 5th Military Hospital with Polyclinic in Cracow, Kraków, Poland https://orcid.org/0009-0001-9118-0769
  • Małgorzata Katra Independent Public Health Care Institution of the Ministry of Interior Affairs and Administration in Kraków, ul. Anonima Galla 25, 30-053 Kraków, Poland https://orcid.org/0009-0007-3772-3455
  • Bogumiła Strzałkowska The Brothers Hospitallers of Saint John Grande Hospital, ul. Trynitarska 11, 31-061 Kraków, Poland https://orcid.org/0000-0002-4760-3808
  • Łukasz Sędek Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Jordana 19, 41-800 Zabrze, Poland https://orcid.org/0000-0001-9384-914X
  • Zenon Czuba Department of Microbiology and Immunology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Jordana 19, 41-800 Zabrze https://orcid.org/0000-0001-8216-4495

DOI:

https://doi.org/10.12775/JEHS.2026.95.74001%20

Keywords

Alzheimer's disease, Parkinson's disease, multiple sclerosis, ALS - Amyotrophic Lateral Sclerosis, probiotics, gut microbiome

Abstract

Background:
Neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), are associated with chronic neuroinflammation and gut microbiota dysbiosis. Increasing evidence suggests that modulation of the microbiota–gut–brain axis with probiotics may represent a novel therapeutic strategy.

Aim:
To summarize current evidence on the effects of probiotic supplementation in AD, PD, MS, and ALS, focusing on potential mechanisms of action and therapeutic outcomes.

Material and methods: A review of scientific literature concerning the influence of gut microbiota on the nervous system through the microbiota-gut-brain axis was conducted. Clinical and preclinical studies evaluating the effectiveness of probiotic therapy in selected neurodegenerative diseases were analyzed.

Results: Probiotic supplementation demonstrated beneficial effects across several neurodegenerative disorders. In AD, probiotics improved cognitive performance, reduced inflammatory markers, and attenuated oxidative stress. In PD, they alleviated gastrointestinal symptoms, improved bowel function, enhanced motor performance, and reduced systemic inflammation. In MS, probiotics decreased pro-inflammatory cytokine expression, promoted anti-inflammatory immune responses, and increased brain-derived neurotrophic factor levels. Experimental ALS studies indicated restoration of gut microbiota, improved intestinal barrier integrity, delayed disease progression, and prolonged survival in animal models.

Conclusion: Probiotics demonstrate promising therapeutic potential in treating neurodegenerative diseases through modulation of gut microbiota and influence on the gut-brain axis. However, further clinical studies are necessary to confirm their clinical significance and biological effects.

References

[1] Mayer EA, Nance K, Chen S. The Gut-Brain Axis. Annu Rev Med 2022;73:439–53. https://doi.org/10.1146/ANNUREV-MED-042320-014032.

[2] Chang CJ, Lin TL, Tsai YL, Wu TR, Lai WF, Lu CC, et al. Next generation probiotics in disease amelioration. J Food Drug Anal 2019;27:615–22. https://doi.org/10.1016/J.JFDA.2018.12.011.

[3] Khan S, Barve KH, Kumar MS. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Curr Neuropharmacol 2020;18:1106–25. https://doi.org/10.2174/1570159X18666200528142429.

[4] Deng H, Dong X, Chen M, Zou Z. Efficacy of probiotics on cognition, and biomarkers of inflammation and oxidative stress in adults with Alzheimer’s disease or mild cognitive impairment-A meta-analysis of randomized controlled trials. Aging 2020;12:4010–39. https://doi.org/10.18632/AGING.102810.

[5] Ho L, Ono K, Tsuji M, Mazzola P, Singh R, Pasinetti GM. Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer’s disease-type beta-amyloid neuropathological mechanisms. Expert Rev Neurother 2018;18:83–90. https://doi.org/10.1080/14737175.2018.1400909.

[6] Angelucci F, Cechova K, Amlerova J, Hort J. Antibiotics, gut microbiota, and Alzheimer’s disease. J Neuroinflammation 2019;16. https://doi.org/10.1186/S12974-019-1494-4.

[8] Dinan TG, Cryan JF. The Microbiome-Gut-Brain Axis in Health and Disease. Gastroenterol Clin North Am 2017;46:77–89. https://doi.org/10.1016/J.GTC.2016.09.007.

[9] Luca M, Mauro M Di, Mauro M Di, Luca A. Gut microbiota in Alzheimer’s disease, depression, and type 2 diabetes mellitus: The role of oxidative stress. Oxid Med Cell Longev 2019;2019. https://doi.org/10.1155/2019/4730539.

[10] Lundmark K, Westermark GT, Olsén A, Westermark P. Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism. Proc Natl Acad Sci U S A 2005;102:6098–102. https://doi.org/10.1073/PNAS.0501814102.

[12] Bonfili L, Cecarini V, Berardi S, Scarpona S, Suchodolski JS, Nasuti C, et al. Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep 2017;7. https://doi.org/10.1038/S41598-017-02587-2.

[13] Xiao J, Katsumata N, Bernier F, Ohno K, Yamauchi Y, Odamaki T, et al. Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Alzheimer’s Disease 2020;77:139–47. https://doi.org/10.3233/JAD-200488.

[14] Tamtaji OR, Heidari-soureshjani R, Mirhosseini N, Kouchaki E, Bahmani F, Aghadavod E, et al. Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer’s disease: A randomized, double-blind, controlled trial. Clinical Nutrition 2019;38:2569–75. https://doi.org/10.1016/J.CLNU.2018.11.034.

[15] Asaoka D, Xiao J, Takeda T, Yanagisawa N, Yamazaki T, Matsubara Y, et al. Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Alzheimer’s Disease 2022;88:75–95. https://doi.org/10.3233/JAD-220148.

[16] Ton AMM, Campagnaro BP, Alves GA, Aires R, Côco LZ, Arpini CM, et al. Oxidative Stress and Dementia in Alzheimer’s Patients: Effects of Synbiotic Supplementation. Oxid Med Cell Longev 2020;2020. https://doi.org/10.1155/2020/2638703.

[17] Kobayashi Y, Kinoshita T, Matsumoto A, Yoshino K, Saito I, Xiao JZ. Bifidobacterium Breve A1 Supplementation Improved Cognitive Decline in Older Adults with Mild Cognitive Impairment: An Open-Label, Single-Arm Study. J Prev Alzheimers Dis 2019;6:70–5. https://doi.org/10.14283/JPAD.2018.32.

[18] Kobayashi Y, Kuhara T, Oki M, Xiao JZ. Effects of bifidobacterium breve a1 on the cognitive function of older adults with memory complaints: A randomised, double-blind, placebo-controlled trial. Benef Microbes 2019;10:511–20. https://doi.org/10.3920/BM2018.0170.

[19] van Soest APM, Hermes GDA, Berendsen AAM, van de Rest O, Zoetendal EG, Fuentes S, et al. Associations between pro-and anti-inflammatory gastro-intestinal microbiota, diet, and cognitive functioning in dutch healthy older adults: The nu-age study. Nutrients 2020;12:1–19. https://doi.org/10.3390/NU12113471.

[20] Candela M, Biagi E, Soverini M, Consolandi C, Quercia S, Severgnini M, et al. Modulation of gut microbiota dysbioses in type 2 diabetic patients by macrobiotic Ma-Pi 2 diet. British Journal of Nutrition 2016;116:80–93. https://doi.org/10.1017/S0007114516001045.

[21] Shi S, Zhang Q, Sang Y, Ge S, Wang Q, Wang R, et al. Probiotic Bifidobacterium longum BB68S Improves Cognitive Functions in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 2023;15. https://doi.org/10.3390/NU15010051.

[22] Ravi AK, Muthukrishnan SK. Combination of Probiotics and Natural Compounds to Treat Multiple Sclerosis via Warburg Effect. Adv Pharm Bull 2022;12:515–23. https://doi.org/10.34172/APB.2022.057.

[23] Parodi B, Kerlero de Rosbo N. The Gut-Brain Axis in Multiple Sclerosis. Is Its Dysfunction a Pathological Trigger or a Consequence of the Disease? Front Immunol 2021;12. https://doi.org/10.3389/FIMMU.2021.718220.

[24] Ghezzi L, Cantoni C, Pinget G V., Zhou Y, Piccio L. Targeting the gut to treat multiple sclerosis. Journal of Clinical Investigation 2021;131. https://doi.org/10.1172/JCI143774.

[25] Camara-Lemarroy CR, Metz L, Meddings JB, Sharkey KA, Wee Yong V. The intestinal barrier in multiple sclerosis: Implications for pathophysiology and therapeutics. Brain 2018;141:1900–16. https://doi.org/10.1093/BRAIN/AWY131.

[26] Atabati H, Yazdanpanah E, Mortazavi H, bajestani SG, Raoofi A, Esmaeili SA, et al. Immunoregulatory Effects of Tolerogenic Probiotics in Multiple Sclerosis. Adv Exp Med Biol 2021;1286:87–105. https://doi.org/10.1007/978-3-030-55035-6_6.

[27] Yang J, Zhang L, Yu C, Yang XF, Wang H. Monocyte and macrophage differentiation: Circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res 2014;2. https://doi.org/10.1186/2050-7771-2-1.

[28] Tankou SK, Regev K, Healy BC, Cox LM, Tjon E, Kivisakk P, et al. Investigation of probiotics in multiple sclerosis. Multiple Sclerosis 2018;24:58–63. https://doi.org/10.1177/1352458517737390.

[29] Rahimlou M, Hosseini SA, Majdinasab N, Haghighizadeh MH, Husain D. Effects of long-term administration of Multi-Strain Probiotic on circulating levels of BDNF, NGF, IL-6 and mental health in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Nutr Neurosci 2022;25:411–22. https://doi.org/10.1080/1028415X.2020.1758887.

[30] Tamtaji OR, Kouchaki E, Salami M, Aghadavod E, Akbari E, Tajabadi-Ebrahimi M, et al. The Effects of Probiotic Supplementation on Gene Expression Related to Inflammation, Insulin, and Lipids in Patients With Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Coll Nutr 2017;36:660–5. https://doi.org/10.1080/07315724.2017.1347074.

[31] Fleming JO, Isaak A, Lee JE, Luzzio CC, Carrithers MD, Cook TD, et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: A phase 1 study. Multiple Sclerosis Journal 2011;17:743–54. https://doi.org/10.1177/1352458511398054.

[32] Maizels RM, Balic A, Gomez-Escobar N, Nair M, Taylor MD, Allen JE. Helminth parasites - Masters of regulation. Immunol Rev 2004;201:89–116. https://doi.org/10.1111/J.0105-2896.2004.00191.X.

[33] Glicksman MA. The preclinical discovery of amyotrophic lateral sclerosis drugs. Https://DoiOrg/101517/174604412011628654 2011;6:1127–38. https://doi.org/10.1517/17460441.2011.628654.

[34] Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013;9:617–28. https://doi.org/10.1038/NRNEUROL.2013.203.

[35] Mazzini L, Mogna L, De Marchi F, Amoruso A, Pane M, Aloisio I, et al. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies. J Clin Gastroenterol 2018;52:S68–70. https://doi.org/10.1097/MCG.0000000000001042.

[36] Rothstein JD. Bench to Bedside Edaravone: A New Drug Approved for ALS. Cell 2017;171. https://doi.org/10.1016/j.cell.2017.10.011.

[37] Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nature Neuroscience 2013 17:1 2013;17:17–23. https://doi.org/10.1038/nn.3584.

[38] Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942–55. https://doi.org/10.1016/S0140-6736(10)61156-7.

[39] Vetrie D. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993 364:6435 1993;364:362–362. https://doi.org/10.1038/364362a0.

[40] Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nature Reviews Neurology 2011 7:11 2011;7:616–30. https://doi.org/10.1038/nrneurol.2011.152.

[41] Quigley EMM. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr Neurol Neurosci Rep 2017;17:94. https://doi.org/10.1007/s11910-017-0802-6.

[42] Rowin J, Xia Y, Jung B, Sun J. Gut inflammation and dysbiosis in human motor neuron disease. Physiol Rep 2017;5:e13443. https://doi.org/10.14814/phy2.13443.

[43] Fang X, Wang X, Yang S, Meng F, Wang X, Wei H, et al. Evaluation of the Microbial Diversity in Amyotrophic Lateral Sclerosis Using High-Throughput Sequencing. Front Microbiol 2016;7. https://doi.org/10.3389/fmicb.2016.01479.

[44] Rowin J, Xia Y, Jung B, Sun J. Gut inflammation and dysbiosis in human motor neuron disease. Physiol Rep 2017;5. https://doi.org/10.14814/phy2.13443.

[45] Tu PH, Raju P, Robinson KA, Gurney ME, Trojanowski JQ, Lee VMY. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A 1996;93:3155–60. https://doi.org/10.1073/PNAS.93.7.3155.

[46] Wu S, Yi J, Zhang YG, Zhou J, Sun J. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep 2015;3:e12356. https://doi.org/10.14814/PHY2.12356.

[47] Zhang Y guo, Wu S, Yi J, Xia Y, Jin D, Zhou J, et al. Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis. Clin Ther 2017;39:322–36. https://doi.org/10.1016/j.clinthera.2016.12.014.

[48] Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 2019 572:7770 2019;572:474–80. https://doi.org/10.1038/s41586-019-1443-5.

[49] Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nature Reviews Disease Primers 2017 3:1 2017;3:1–21. https://doi.org/10.1038/nrdp.2017.13.

[50] Schapira AHV. Science, medicine, and the future: Parkinson’s disease. BMJ : British Medical Journal 1999;318:311. https://doi.org/10.1136/BMJ.318.7179.311.

[51] Beitz JM. Parkinson’s disease: a review. Front Biosci (Schol Ed) 2014;6:65–74. https://doi.org/10.2741/S415.

[52] Przedborski S. The two-century journey of Parkinson disease research. Nat Rev Neurosci 2017;18:251–9. https://doi.org/10.1038/NRN.2017.25.

[53] Reich SG, Savitt JM. Parkinson’s Disease. Med Clin North Am 2019;103:337–50. https://doi.org/10.1016/J.MCNA.2018.10.014.

[54] Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, Van Der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 2004;44:595–600. https://doi.org/10.1016/j.neuron.2004.10.023.

[55] Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science 2003;302:841. https://doi.org/10.1126/SCIENCE.1090278.

[56] Jenner P, Hunot, Olanow, Beal, Kordower, Tatton, et al. Oxidative stress in Parkinson’s disease. Ann Neurol 2003;53:S26–38. https://doi.org/10.1002/ANA.10483.

[57] Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord 2012;18 Suppl 1. https://doi.org/10.1016/S1353-8020(11)70065-7.

[58] Scheperjans F, Aho V, Pereira PAB, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord 2015;30:350–8. https://doi.org/10.1002/MDS.26069.

[59] Chandra S, Alam MdT, Dey J, Sasidharan BCP, Ray U, Srivastava AK, et al. Healthy Gut, Healthy Brain: The Gut Microbiome in Neurodegenerative Disorders. Curr Top Med Chem 2020;20:1142–53. https://doi.org/10.2174/1568026620666200413091101.

[60] Spielman LJ, Gibson DL, Klegeris A. Unhealthy gut, unhealthy brain: The role of the intestinal microbiota in neurodegenerative diseases. Neurochem Int 2018;120:149–63. https://doi.org/10.1016/j.neuint.2018.08.005.

[61] Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 2015;17:565–76. https://doi.org/10.1016/J.CHOM.2015.04.011.

[62] Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. Cell 2016;167:1469. https://doi.org/10.1016/J.CELL.2016.11.018.

[63] Fang X. Microbial treatment: the potential application for Parkinson’s disease. Neurol Sci 2019;40:51–8. https://doi.org/10.1007/S10072-018-3641-6.

[64] Gazerani P. Probiotics for Parkinson’s Disease. Int J Mol Sci 2019;20. https://doi.org/10.3390/IJMS20174121.

[65] Cassani E, Privitera G, Pezzoli G, Pusani C, Madio C, Iorio L, et al. Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterol Dietol 2011;57:117–21.

[66] Shih DQ, Kwan LY. All Roads Lead to Rome: Update on Rome III Criteria and New Treatment Options. Gastroenterol Rep 2007;1:56.

[67] Barichella M, Pacchetti C, Bolliri C, Cassani E, Iorio L, Pusani C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease. Neurology 2016;87:1274–80. https://doi.org/10.1212/WNL.0000000000003127.

[68] Ibrahim A, Raja Ali RA, Abdul Manaf MR, Ahmad N, Tajurruddin FW, Qin WZ, et al. Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson’s disease: A randomised controlled trial. PLoS One 2020;15. https://doi.org/10.1371/journal.pone.0244680.

[69] Tan AH, Lim SY, Chong KK, A Manap MAA, Hor JW, Lim JL, et al. Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study. Neurology 2021;96:e772–82. https://doi.org/10.1212/WNL.0000000000010998.

[70] Du Y, Li Y, Xu X, Li R, Zhang M, Cui Y, et al. Probiotics for constipation and gut microbiota in Parkinson’s disease. Parkinsonism Relat Disord 2022;103:92–7. https://doi.org/10.1016/j.parkreldis.2022.08.022.

[71] Georgescu D, Ancusa OE, Georgescu LA, Ionita I, Reisz D. Nonmotor gastrointestinal disorders in older patients with Parkinson’s disease: Is there hope? Clin Interv Aging 2016;11:1601–8. https://doi.org/10.2147/CIA.S106284.

[72] Tamtaji OR, Taghizadeh M, Daneshvar Kakhaki R, Kouchaki E, Bahmani F, Borzabadi S, et al. Clinical and metabolic response to probiotic administration in people with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition 2019;38:1031–5. https://doi.org/10.1016/j.clnu.2018.05.018.

[73] Borzabadi S, Oryan S, Eidi A, Aghadavod E, Kakhaki RD, Tamtaji OR, et al. The effects of probiotic supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Arch Iran Med 2018;21:289–95.

[74] Magistrelli L, Amoruso A, Mogna L, Graziano T, Cantello R, Pane M, et al. Probiotics May Have Beneficial Effects in Parkinson’s Disease: In vitro Evidence. Front Immunol 2019;10. https://doi.org/10.3389/FIMMU.2019.00969.

[75] Calvo AC, Valledor-Martín I, Moreno-Martínez L, Toivonen JM, Osta R. Lessons to Learn from the Gut Microbiota: A Focus on Amyotrophic Lateral Sclerosis. Genes 2022, Vol 13, Page 865 2022;13:865. https://doi.org/10.3390/GENES13050865.

Journal of Education, Health and Sport

Downloads

  • PDF

Published

2026-11-16

How to Cite

1.
SZCZĘSNY, Mikołaj, SZAREK, Rafał, KATRA, Małgorzata, STRZAŁKOWSKA, Bogumiła, SĘDEK, Łukasz and CZUBA, Zenon. Probiotics in neurodegenerative disorders. Journal of Education, Health and Sport. Online. 16 November 2026. Vol. 95. [Accessed 17 November 2026]. DOI 10.12775/JEHS.2026.95.74001 .
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 95 (2026)

Section

Health Sciences

License

Copyright (c) 2026 Mikołaj Szczęsny, Rafał Szarek, Małgorzata Katra, Bogumiła Strzałkowska, Łukasz Sędek, Zenon Czuba

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 30
Number of citations: 0

Search

Search

Browse

  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

Alzheimer's disease, Parkinson's disease, multiple sclerosis, ALS - Amyotrophic Lateral Sclerosis, probiotics, gut microbiome
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop